TYBOURNE CAPITAL MANAGEMENT (HK) LTD 13D and 13G filings for Zentalis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 10:52 am Sale | 2022-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,231,427 3.900% | -396,982 (-15.10%) | Filing |
| 2022-02-14 12:06 pm Sale | 2021-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 5.800% | -36,000 (-1.35%) | Filing |
| 2020-05-29 09:21 am Purchase | 2020-05-29 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,664,409 7.400% | 2,664,409 (New Position) | Filing |